Category: CDE

Categories
CDE Diabetes

Flashcards: Screening for the Presence of Cardiovascular Disease (Chapter 24)

Cardiovascular disease is the leading cause of death in diabetes, yet a significant proportion of patients present with “silent” ischemia—suffering a myocardial infarction without prior warning symptoms. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the 2018 Clinical Practice Guidelines regarding risk stratification, the specific indications for resting ECGs versus stress testing, and the criteria for specialist referral.

Key Topics Covered:

  • The “Silent” Threat: Understanding why traditional symptom-based assessment may fail in diabetes, as many individuals do not experience chest pain before a cardiac event.

  • Screening Protocols: Memorizing the recommendations for baseline resting ECGs (e.g., age >40, duration of diabetes >15 years) and the frequency of repeat testing.

  • Stress Testing Indications: Distinguishing between patients who require exercise stress testing (e.g., those with typical/atypical symptoms or PAD) and the recommendation against routine screening in asymptomatic individuals.

  • Prognostic Assessment: Identifying when exercise stress testing is most useful for assessing long-term prognosis in high-risk groups.

  • Referral Criteria: Recognizing the clinical signs—such as unexplained dyspnea or carotid bruits—that warrant immediate referral to a cardiac specialist.

Categories
CDE Diabetes

Practice Exam: Screening for the Presence of Cardiovascular Disease (Chapter 24)

Individuals with diabetes are at a significantly higher risk of developing cardiovascular disease (CVD) and often present with “silent” ischemia, meaning they may suffer a myocardial infarction without experiencing typical chest pain. The 2018 Clinical Practice Guidelines provide specific criteria for when—and how—to screen for coronary artery disease (CAD) to ensure resources are used effectively.

This practice exam tests your ability to identify which patients require routine screening (e.g., resting ECG) versus those who require further investigation (e.g., stress testing) based on their symptom profile and risk factors.

Key Concepts Covered in This Exam:

  • The “Silent” Threat: Understanding that a large proportion of people with diabetes will have no symptoms prior to a fatal or nonfatal myocardial infarction.

  • Resting ECG Guidelines: Identifying who should receive a baseline resting ECG and how often it should be repeated (e.g., every 3 to 5 years) for patients with specific risk factors.

  • Indications for Stress Testing: Recognizing that routine stress testing is not recommended for asymptomatic individuals, but is indicated for those with typical or atypical cardiac symptoms, or associated diseases like peripheral artery disease (PAD).

  • Assessment of Prognosis: Knowing when exercise stress testing is useful for assessing prognosis in high-risk individuals versus when functional imaging might be preferred.

  • Referral Criteria: Determining when a patient should be referred to a cardiac specialist for further evaluation.

1. What percentage of older asymptomatic individuals with type 2 diabetes and microalbuminuria have silent MI?

2. Which of the following CVD risk factors qualifies as an indication for resting ECG screening according to the guidelines?

3. What percentage of people with diabetes will die from heart disease?

4. A 58-year-old man with type 2 diabetes undergoes exercise stress SPECT myocardial perfusion imaging and achieves 11 METs despite having significant perfusion defects. What is the expected annualized cardiac event rate for this patient?

5. Case 6: A 48-year-old asymptomatic man with type 2 diabetes undergoes coronary CTA and has no evidence of coronary artery disease. What is the prognostic warranty period for this patient based on the normal coronary CTA result?

6. What coronary artery calcium (CAC) score threshold is used as an indication for exercise ECG stress testing?

7. What is the most predictive clinical observation for coronary artery disease in persons with or without diabetes?

8. At what exercise capacity threshold should individuals with diabetes demonstrating ischemia be referred to a cardiac specialist?

9. Which of the following resting ECG abnormalities limits the diagnostic accuracy of an exercise ECG stress test?

10. Case 9: A 42-year-old woman with well-controlled type 2 diabetes is planning to start high-intensity interval training. According to the guidelines, should a resting ECG be performed before she begins this exercise program?

11. What is the approximate increased risk of peripheral arterial disease (PAD) in people with type 2 diabetes compared to the population without diabetes?

12. How often should a resting ECG be repeated in individuals with diabetes who meet screening criteria?

13. What is the odds ratio for ST-T abnormalities at rest as a predictor of silent ischemia in people with diabetes?

14. What is the annual CAD event rate in people with diabetes and silent ischemia?

15. Case 7: A 62-year-old woman with type 2 diabetes has absent dorsalis pedis and posterior tibial pulses on examination. What is the significance of absent peripheral pulses in this patient?

16. Approximately what proportion of myocardial infarctions in people with diabetes occur without recognized or typical symptoms (silent MIs)?

17. According to the guidelines, which of the following is an indication for exercise ECG stress testing as the initial test?

18. A 52-year-old woman with type 2 diabetes complains of unexplained dyspnea on exertion. Her resting ECG is normal and she has no baseline ST abnormalities. What is the recommended initial investigation for CAD in this patient?

19. What is the strongest and most consistent prognostic marker identified during exercise ECG stress testing?

20. A 45-year-old man with type 2 diabetes of 8 years duration presents for a routine visit. He has hypertension, is a current smoker, and has a BMI of 32 kg/m². He is asymptomatic. According to the guidelines, should a resting ECG be performed in this patient?

21. A 55-year-old woman with type 2 diabetes has severe peripheral neuropathy and foot pathology that prevents her from walking on a treadmill. She requires cardiac stress testing. What type of stress test is appropriate for this patient?

22. Case: A 50-year-old man with type 2 diabetes has a history of transient ischemic attack (TIA) 6 months ago. He is currently asymptomatic for cardiac symptoms. According to the guidelines, should he undergo exercise ECG stress testing?

23. How do major CVD events in type 1 diabetes compare temporally to matched controls without diabetes?

24. What is the sensitivity and specificity of an abnormal posterior tibial pulse for detection of PAD?

25. In what percentage of individuals with diabetes will typical chest pain or discomfort be absent?

26. Case: A patient with type 2 diabetes has no coronary artery calcium (CAC score = 0) detected on CT imaging. What is the prognostic significance of no detectable CAC in people with diabetes?

27. The age-adjusted relative risk for CVD in type 1 diabetes is how many times that of the general population?

28. Case 3: A 60-year-old man with type 2 diabetes needs cardiac stress testing but has a left bundle branch block on his resting ECG. What type of stress test should be performed?

29. Case: A 45-year-old woman with type 1 diabetes is concerned about her cardiovascular risk compared to a woman without diabetes. What is the hazard ratio for major CAD events in women with type 1 diabetes compared to the general population?

30. Case 8: A 35-year-old man with type 1 diabetes of 20 years duration has no cardiac symptoms. He asks about his cardiovascular risk. According to the guidelines, should a resting ECG be performed?


 

Categories
CDE Diabetes

Study Guide: Screening for the Presence of Cardiovascular Disease (Chapter 24)

1. Overview & Rationale

Cardiovascular disease (CVD) is the leading cause of death in diabetes. The presentation of CVD in this population is often atypical.

  • The “Silent” Threat: A large proportion of people with diabetes may have no symptoms (silent ischemia) before a fatal or non-fatal myocardial infarction (MI).

  • Risk Status: People with diabetes are at higher risk of developing heart disease at an earlier age compared to those without diabetes.

  • The Goal: To identify individuals with established severe coronary artery disease (CAD) who might benefit from revascularization or intensive medical therapy.

2. Screening Modalities

Different tests are used based on the patient’s symptoms and ability to exercise.

A. Resting Electrocardiogram (ECG)

  • Utility: Can detect previous silent MI, Left Ventricular Hypertrophy (LVH), or rhythm abnormalities.

  • Limitation: A normal resting ECG does not rule out CAD (it can be normal in >50% of patients with confirmed CAD).

B. Exercise Stress Testing (EST)

  • Indication: Useful for assessing prognosis in high-risk individuals.

  • Challenges: Exercise capacity is frequently impaired in people with diabetes due to obesity, neuropathy, or deconditioning, which can limit the test’s accuracy.

C. Stress Imaging (MPI or Echocardiography)

  • Indication: Used when the patient cannot exercise adequately or has a baseline ECG that is uninterpretable (e.g., Left Bundle Branch Block, LVH, paced rhythm).

  • Types:

    • Myocardial Perfusion Imaging (MPI): Uses a vasodilator (e.g., dipyridamole/adenosine) to mimic exercise stress.

    • Stress Echocardiography: Uses dobutamine to increase heart rate.

D. Coronary Artery Calcium (CAC) Scoring

  • Utility: Excellent for risk stratification (determining if a patient is low vs. high risk).

  • Limitation: While it predicts risk, studies have not consistently shown that screening with CAC improves clinical outcomes compared to standard intensive risk factor management.

3. The "Asymptomatic" Controversy (High Yield)

One of the most critical concepts for the CDE exam is whether to screen patients who feel fine.

  • Routine Screening: Routine screening for CAD in asymptomatic people with diabetes is NOT recommended.

  • The Evidence: The DIAD Study (Detection of Ischemia in Asymptomatic Diabetics) showed that screening asymptomatic patients with stress imaging did not reduce cardiac events (MI or death) compared to standard care.

    • Why? Medical management (statins, BP control, A1C control) is now so effective that identifying mild/moderate ischemia early doesn’t necessarily change the treatment plan or outcome.

4. Who Should Be Tested? (The Indications)

While routine screening is out, targeted testing is in.

1. Resting ECG (Baseline & Repeat): Consider for:

  • Age years.

  • Duration of diabetes years (Type 1).

  • Presence of microvascular complications (retinopathy, nephropathy, neuropathy).

  • Frequency: Repeat every 2 years in these groups.

2. Stress Testing (ECG or Imaging): Mandatory for:

  • Typical or Atypical cardiac symptoms (e.g., unexplained shortness of breath).

  • Associated diseases: Peripheral Artery Disease (PAD) or Carotid Artery Disease.

  • Sedentary individuals planning to begin vigorous or intense exercise.

  • High-risk occupations (e.g., airline pilots).

5. Diabetes Canada Clinical Practice Guidelines Recommendations

ey takeaways from the “Recommendations” section (Page S175).

  1. Baseline ECG: A resting ECG should be performed in individuals with:

    • Age years [Grade D, Consensus].

    • Duration of diabetes years (Type 1) [Grade D, Consensus].

    • Microvascular complications [Grade D, Consensus].

    • (Repeat every 2 years).

  2. No Routine Screening: Routine cardiac screening (stress test/imaging) is not recommended for asymptomatic adults with diabetes [Grade A, Level 1A].

  3. Indications for Stress Testing: Stress testing should be performed for:

    • Typical or atypical cardiac symptoms (e.g., unexplained dyspnea) [Grade C, Level 3].

    • Signs of associated PAD or Carotid disease [Grade D, Consensus].

    • Sedentary individuals planning vigorous exercise [Grade D, Consensus].

  4. Choice of Test:

    • Exercise ECG is the initial test if the patient can exercise and has a normal resting ECG [Grade D, Consensus].

    • Pharmacologic stress echo or nuclear imaging should be used if the patient cannot exercise or has resting ECG abnormalities [Grade D, Consensus].

Reference:

Poirier P, Bertrand OF, Leipsic J, Mancini GBJ, Raggi P, Roussin A. Screening for the Presence of Cardiovascular Disease. Canadian Journal of Diabetes. 2018;42:S170-S177. doi:10.1016/j.jcjd.2017.10.025
Categories
CDE Diabetes

Flashcards: Cardiovascular Protection in People with Diabetes (Chapter 23)

Cardiovascular disease is the leading cause of death for people with diabetes. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the comprehensive strategies outlined in the 2018 Clinical Practice Guidelines—from vascular protection medications to lifestyle interventions—to aggressively lower morbidity and mortality.

Key Topics Covered:

  • Risk Assessment: Differentiating between proximate (<10 years) and lifetime risk, particularly for younger patients who may have a high relative risk despite low short-term absolute risk.

  • The “ABCDEs” Strategy: Memorizing the components of comprehensive vascular protection: A1C, Blood pressure, Cholesterol, Drugs, Exercise/Healthy Eating, Screening for complications, and Smoking cessation.

  • Lipid Management: Recalling the specific indications for statin therapy and the primary target of LDL-C 2.0 mmol/L (or >50% reduction).

  • Cardioprotective Agents: Identifying the specific roles of SGLT2 inhibitors and GLP-1 receptor agonists in reducing major cardiovascular events (MACE) and heart failure hospitalization.

  • Antiplatelet Therapy: Understanding the nuances of aspirin use for secondary prevention versus the limited indications for primary prevention.

Categories
CDE Diabetes

Practice Exam: Cardiovascular Protection in People with Diabetes (Chapter 23)

Cardiovascular disease (CVD) remains the leading cause of death for people living with diabetes. The 2018 Clinical Practice Guidelines emphasize that diabetes significantly accelerates the natural history of CVD, making aggressive risk reduction a cornerstone of management.

This practice exam tests your ability to implement the comprehensive “ABCDEs” of cardiovascular protection, ranging from lifestyle interventions to the use of cardioprotective pharmacotherapy.

Key Concepts Covered in This Exam:

  • Risk Assessment: Differentiating between proximate (<10 years) and lifetime risk, especially in younger patients who may have low short-term risk but high relative risk.

  • Lipid Management: Identifying the indications for statin therapy and the specific targets for Low-Density Lipoprotein Cholesterol (LDL-C).

  • Blood Pressure Control: Applying the correct targets and selecting preferred pharmacological agents (e.g., ACE inhibitors or ARBs) for renal and cardiovascular protection.

  • Cardioprotective Agents: Recognizing the specific roles of SGLT2 inhibitors and GLP-1 receptor agonists in reducing cardiovascular events independent of glycemic control.

  • Antiplatelet Therapy: Understanding when aspirin therapy is indicated for secondary prevention versus the nuances of primary prevention.

Please go to Practice Exam: Cardiovascular Protection in People with Diabetes (Chapter 23) to view this quiz

Categories
CDE Diabetes

Study Guide: Cardiovascular Protection in People with Diabetes (Chapter 23)

1. Overview & Pathophysiology

Cardiovascular disease (CVD) is the primary cause of death for people with diabetes.

  • Vascular Age: Diabetes significantly accelerates vascular aging. Having diabetes confers a CVD risk equivalent to aging approximately 15 years.
  • Proximate vs. Lifetime Risk: While young people with diabetes may have low proximate (<10 years) risk, their lifetime risk is extremely high. Therefore, early intervention is justified.

  • The “Vascular Protection” Concept: Multifactorial intervention (treating lipids, BP, glucose, and lifestyle simultaneously) provides benefit greater than the sum of its parts.

    • Key Study: The STENO-2 Trial showed that intensive multifactorial intervention reduced major adverse cardiac events (MACE) by 53% and mortality by 20%.

 

2. Patient Education: The ABCDEs

The guidelines recommend teaching patients the “ABCDEs” to reduce heart attack and stroke risk :

  • A = A1C (Target usually ).

  • B = BP (Target mmHg).

  • C = Cholesterol (LDL-C mmol/L).

  • D = Drugs to protect the heart (ACEi/ARBs, Statins, and specific glucose-lowering agents like SGLT2i/GLP-1 RA).

  • E = Exercise / Eating (Healthy behaviors).

  • S = Stop Smoking (and manage Stress)

3. Pharmacotherapy for CV Protection

This section focuses on the “D” (Drugs) of the ABCDEs.

A. Lipid-Modifying Therapies (Statins)

Statins are recommended based on risk categories, not just LDL levels.

  • Who needs a Statin?
    1. Clinical CVD: Anyone with established cardiovascular disease.
    2. Age 40 years: All individuals with Type 2 diabetes.
    3. Age < 40 years: Only if “High Risk,” defined as:
      • Diabetes duration years (and age ).
      • Microvascular complications present.
      • Warrants therapy based on other risk factors (e.g., Familial Hypercholesterolemia).
  • Second-Line: If LDL goals are not met, Ezetimibe or PCSK-9 inhibitors (Evolocumab) may be added.

B. RAAS Inhibition (ACE Inhibitors / ARBs)

  • Indication:
    • Clinical CVD: All patients.
    • Age 55 years: If they have one additional CV risk factor OR end-organ damage (albuminuria, retinopathy, LVH).
    • Microvascular Complications: To delay progression (e.g., albuminuria).
  • Note: The previous recommendation to treat everyone regardless of risk factors was removed in 2018. Now requires an additional risk factor or end-organ damage.
  • Pregnancy: ACEi/ARBs and Statins are contraindicated in pregnancy.

C. Antiplatelet Therapy (ASA / Aspirin)

  • Secondary Prevention: YES. Routine use (81–162 mg) is recommended for those with established CVD.
  • Primary Prevention: NO. ASA should not be used routinely for primary prevention due to bleeding risks outweighing benefits.
    • Exception: May be considered on an individual basis for those with very high risk/multiple risk factors.
  • Clopidogrel: Use if ASA intolerant.

D. Antihyperglycemic Agents with CV Benefit

For patients with Type 2 diabetes and clinical CVD who are not at glycemic target, specific agents with proven CV benefit should be prioritized:

  • Empagliflozin (SGLT2i): Reduced CV mortality and all-cause mortality (EMPA-REG OUTCOME).

  • Liraglutide (GLP-1 RA): Reduced MACE (CV death, non-fatal MI, stroke) (LEADER).

  • Canagliflozin (SGLT2i): Reduced MACE (CANVAS), but noted increased amputation risk in trial.

(NOTE: Since the publication of the guidelines semaglutide po/sc and tirzepatide have demonstrated significant effect on MACE)

4. Glycemic Control & CV Outcomes (The Trials)

Understanding the difference between early and late intervention is key.

  • Early Intervention (DCCT/UKPDS): Intensive control early in the disease course has a “legacy effect,” reducing CV events long-term.
  • Late Intervention (ACCORD/ADVANCE/VADT): In older patients with long-standing diabetes and CVD risk, intensive glucose lowering (targeting A1C < 6.0-6.5%) did NOT reduce CV events and increased mortality in the ACCORD trial.
    • Takeaway: Aggressive A1C targets may be dangerous in high-risk, long-standing diabetes.

5. Diabetes Canada Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page S169).

  1. Statin Therapy: Recommended for all with clinical CVD, or Type 2 diabetes Age 40, or young patients with microvascular complications/long duration [Grade A/D].
  2. ACEi/ARB: Recommended for clinical CVD, or Age 55 with add-on risk/organ damage, or microvascular complications [Grade A/D].
  3. ASA: Recommended for Secondary Prevention [Grade B]. Not recommended routinely for Primary Prevention [Grade A].
  4. CVD Benefit Agents: In adults with T2D and clinical CVD, add Empagliflozin [Grade A, Level 1A], Liraglutide [Grade A, Level 1A], or Canagliflozin [Grade C, Level 2] if not at target.

Reference:

Stone JA, Houlden RL, Lin P, Udell JA, Verma S. Cardiovascular Protection in People With Diabetes. Canadian Journal of Diabetes. 2018;42:S162-S169. doi:10.1016/j.jcjd.2017.10.024
Categories
CDE Diabetes

Flashcards: Complementary and Alternative Medicine for Diabetes (Chapter 22)

With nearly half of all people with diabetes reporting the use of complementary or alternative medicine (CAM), it is crucial for healthcare professionals to separate evidence-based potential from proven inefficacy or harm. These flashcards are designed to help you quickly recall the 2018 Clinical Practice Guidelines regarding the efficacy, safety, and drug interactions of various natural health products (NHPs) and alternative modalities.

Key Topics Covered:

  • Efficacy Evidence: Distinguishing between NHPs with potential benefits (e.g., fenugreek, flaxseed) and those that have consistently failed to show benefit in large trials (e.g., cinnamon, chromium, vitamin D)

  • Safety & Regulation: Understanding the risks of contamination and the importance of recommending only products with a Natural Product Number (NPN).

  • Drug-Herb Interactions: Identifying critical interactions, such as St. John’s Wort inducing CYP3A4 and reducing the efficacy of statins and other medications.

  • Adverse Effects: Recalling specific risks, such as the abortifacient properties of bitter melon or the hypoglycemic risk of products adulterated with glyburide.

  • Mind-Body Therapies: Reviewing the evidence for yoga and other modalities in improving glycemic control and cardiovascular risk factors .

Categories
CDE Diabetes

Practice Exam: Complementary and Alternative Medicine for Diabetes (Chapter 22)

With 25% to 57% of people with diabetes reporting the use of complementary or alternative medicine, it is essential for healthcare professionals to understand the current evidence base. While many patients seek these therapies to align with their values or due to dissatisfaction with conventional care, the evidence for efficacy and safety varies significantly.

This practice exam tests your knowledge of the 2018 Clinical Practice Guidelines regarding Natural Health Products (NHPs), mind-body practices, and the critical importance of identifying potential drug-herb interactions.

Key Concepts Covered in This Exam:

  • Prevalence & Disclosure: Recognizing the high rate of CAM usage and the recommendation that healthcare providers must actively ask patients about their use of these therapies.
  • Evidence of Efficacy: Identifying which NHPs have shown potential A1C reduction (0.5%) in small trials (e.g., fenugreek, flaxseed) versus those that have failed to show consistent benefit in larger trials (e.g., cinnamon, chromium, vitamin D).
  • Safety & Regulation: Understanding the risks of adulteration and the importance of using products with a Natural Product Number (NPN), as well as specific risks like hepatotoxicity or hypoglycemia.
  • Drug Interactions: Knowing well-documented interactions, such as the effect of St. John’s Wort on cytochrome P450 3A4 (CYP3A4) and its impact on statins and other medications.
  • Mind-Body Modalities: Reviewing the evidence for non-pharmacologic approaches like yoga, which may offer benefits for glycemic control and lipid profiles.

Please go to Practice Exam: Complementary and Alternative Medicine for Diabetes (Chapter 22) to view this quiz

Categories
CDE Diabetes

Study Guide: Complementary and Alternative Medicine (Chapter 22)

1. Overview & Definitions

Usage of Complementary and Alternative Medicine (CAM) is high among people with diabetes (estimates range from 25% to 57%).

  • Complementary: Used together with conventional medicine.

  • Alternative: Used in place of conventional medicine.

  • Natural Health Products (NHP): Include vitamins, minerals, herbal remedies, and traditional medicines. In Canada, these are regulated and have a Natural Product Number (NPN), but evidence quality is generally lower than for pharmaceuticals.

2. Efficacy of Natural Health Products (NHPs)

The guidelines categorize NHPs based on their ability to lower A1C in randomized controlled trials (RCTs).

A. Products showing potential A1C reduction ( 0.5%) These have shown promise in small trials, but evidence is insufficient to recommend them for widespread use.

  • Glycemic Control: Aloe vera (oral), Berberine, Fenugreek (Trigonella foenum-graecum), Ginger, Magnesium, Silymarin (Milk Thistle), Flaxseed oil (high dose).
  • Note on Berberine: Meta-analysis shows it may reduce triglycerides and increase HDL more than traditional drugs, and lower BP when used as an adjunct.

B. Products with No Benefit or Conflicting Evidence Despite popular belief, these have generally failed to consistently show benefit for glycemic control in robust studies.

  • Cinnamon: Conflicting results; some studies show benefit, others do not.
  • Chromium: Meta-analyses show no benefit on A1C, lipids, or weight, despite early theories about deficiency causing insulin resistance.
  • Vitamin D: While important for bone health, supplementation does not improve glycemic control (A1C) in people with diabetes.
  • Others with lack of benefit: Vitamin C, Vitamin E, Ginseng (variable/heterogeneous), Green Tea (Camellia sinensis).

3. Safety Concerns & Interactions (High Yield for CDE Exam)

CDEs must be vigilant about “natural” products having pharmacological effects or contaminants.

  • Xiaoke Pills: A Traditional Chinese Medicine (TCM) that often contains glibenclamide (glyburide). Patients taking this may be at risk of severe hypoglycemia, especially if taking other sulfonylureas.
  • St. John’s Wort (Hypericum perforatum): Induces Cytochrome P450 3A4 (CYP3A4). It can reduce the effectiveness of many drugs, including statins and some antihypertensives.
  • Bitter Melon (Momordica charantia): Used for glucose lowering, but is an abortifacient and should be avoided in pregnancy.
  • Nettle: Has insulin secretagogue activity; potential additive hypoglycemia risk.

4. Other CAM Modalities

A. Mind-Body Practices

  • Xiaoke Pills: A Traditional Chinese Medicine (TCM) that often contains glibenclamide (glyburide). Patients taking this may be at risk of severe hypoglycemia, especially if taking other sulfonylureas.
  • St. John’s Wort (Hypericum perforatum): Induces Cytochrome P450 3A4 (CYP3A4). It can reduce the effectiveness of many drugs, including statins and some antihypertensives.
  • Bitter Melon (Momordica charantia): Used for glucose lowering, but is an abortifacient and should be avoided in pregnancy.
  • Nettle: Has insulin secretagogue activity; potential additive hypoglycemia risk.

4. Other CAM Modalities

A. Mind-Body Practices

  • Yoga: Regular practice (e.g., 3 times/week) may improve A1C, lipids, and blood pressure. Some data suggests it is more effective than walking or Tai Chi for lowering A1C.
  • Tai Chi: Little evidence for glycemic benefit, though may improve quality of life.

B. Physical Treatments

  • Acupuncture: No evidence for improving A1C. Some low-quality evidence suggests benefit for diabetic neuropathy symptoms or gastroparesis symptoms .
  • Chelation Therapy (EDTA): The TACT trial showed a reduction in cardiovascular events in patients with prior MI and diabetes.
  • Reflexology: Small studies suggest potential benefit for neuropathy pain and glycemic control.

5. Diabetes Canada Clinical Practice Guidelines Recommendations

Key takeaways from the “Recommendations” section (Page S157).

  1. Ask the Question: Health-care providers should ask about the use of complementary and alternative medicine in people with diabetes [Grade D, Consensus].
  2. Insufficient Evidence: There is insufficient evidence to make a recommendation regarding the efficacy and safety of CAM for individuals with diabetes [Grade D, Consensus].
    • Interpretation: Do not actively recommend these products for diabetes management, but be prepared to discuss safety/interactions if patients use them.

 

Reference:

Grossman LD, Roscoe R, Shack AR. Complementary and Alternative Medicine for Diabetes. Canadian Journal of Diabetes. 2018;42:S154-S161. doi:10.1016/j.jcjd.2017.10.023
Categories
CDE Diabetes

Flashcards: Diabetes and Driving (Chapter 21)

Driving with diabetes requires careful management to ensure safety for the driver and the public. These flashcards are designed to help pharmacists and healthcare professionals quickly recall the 2018 Clinical Practice Guidelines regarding medical assessments, the “safe to drive” blood glucose thresholds, and the responsibilities of both patients and providers.

Key Topics Covered:

  • Assessment Intervals: Recalling that all drivers with diabetes need a medical exam every 2 years, while commercial drivers have stricter requirements [cite: Ch21-Diabetes-and-Driving.pdf].

  • The “40-Minute Rule”: Memorizing the protocol that if blood glucose is <4.0 mmol/L, driving must cease until treatment raises glucose to at least 5.0 mmol/L and 40 minutes have passed.

  • Hypoglycemia Unawareness: Identifying this as a major risk factor that may require more frequent testing (every 2 hours) or Continuous Glucose Monitoring (CGM) while driving.

  • Commercial vs. Private: Differentiating the reporting and assessment standards for commercial drivers, who face higher scrutiny due to increased road exposure.

  • Patient Duty: Understanding the patient’s obligation to report any severe hypoglycemic event to their healthcare team and licensing body.